PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Sarcopenia

Drugs in development · updated 30 October 2026

Sarcopenia: drugs in development

As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for sarcopenia. 5 are experimental, that is not yet approved in the United States.

11Active trials
5Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
AMC6156II1NCT07072195
EN001I–II1NCT07808905
IsomyosamineII1NCT06942182
PLH-2301II1NCT07390552
TJ0113II1NCT07620938

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
Vitamin DIII1NCT06708741
TirzepatideZepbound, MounjaroII2NCT07747805
Nandrolone DecanoateDeca-Durabolin®II1NCT05978206
OxandroloneII1NCT06974526
ValineEarly I1NCT07437053

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D055948 “Sarcopenia”.

ItalianoFrançaisDeutsch